The start of 2025 has sent a strong signal for Abbott - despite changing global market conditions, the company has managed to maintain a positive trend. The first quarter showed that the different parts of the company are able to respond flexibly to the current challenges, while at the same time taking advantage of the opportunities that are emerging in different areas of healthcare. Despite the decline in demand for COVID-19 tests, the company's overall performance remains on an upward trajectory, mainly due to steady interest in medical devices.

What's happening?

It turns out that the key to the current performance is balance - between segments, between traditional markets and new areas of interest, and between short-term fluctuations and long-term direction. Although some areas, such as diagnostics, have faced pressures, other divisions have more than compensated. As a result, the company enters the next part of the year with a clear plan and a focus on developing products and…